Interventions of Interest

  • Imetelstat (Rytelo, Geron Corporation)

Myelodysplastic syndromes (MDS) are an uncommon group of disorders characterized by abnormal blood-forming cells in the bone marrow, resulting in the reduction of peripheral blood cells, an elevated risk of acute myeloid leukemia (AML), and reduced survival.
Anemia (low red blood cell counts), thrombocytopenia (low platelet counts), and leukopenia (low white blood cell counts) are common among patients with MDS. The most common and bothersome symptom of these effects is severe fatigue, although they may also cause bleeding, night sweats, bone pain, fever, weight loss, and recurrent infections.

For questions please contact Becca Piltch, Program Manager, bpiltch@icer.org.

View the Key Stakeholder List.